Article

Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.

Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
Journal of Clinical Pharmacy and Therapeutics (Impact Factor: 2.1). 08/2008; 33(4):439-49. DOI: 10.1111/j.1365-2710.2008.00936.x
Source: PubMed

ABSTRACT Clopidogrel is an important antiplatelet drug that is effective in preventing thrombotic events, especially for patients undergoing percutaneous coronary intervention. The therapeutic usefulness of clopidogrel has been limited by documented inter-individual heterogeneity in platelet inhibition, which may be attributable to known clopidogrel pharmacokinetic variability. The objective of this study was to assess the influence of smoking cigarettes and abnormal body weight on the pharmacokinetics of clopidogrel.
Seventy-six healthy adult male volunteers were selected randomly. Each subject received a single 75 mg oral dose of clopidogrel after overnight fast. Clopidogrel carboxylate plasma levels were measured and non-compartmental analysis was used to determine peak plasma concentration (C(max)), time to peak plasma concentration (T(max)), elimination half-life (t(1/2e)), and area under the curve (AUC(0-->infinity)).
One-third of volunteers were smokers (n = 27) and one-half had abnormal body weight (n = 39). Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001). Smoking behaviour had no influence on C(max) (P = 0.3) and T(max) (P = 0.7). There was no statistically significant difference in C(max), AUC(0-->infinity), T(max) and t(1/2e) between volunteers with abnormal body weight and normal body weight. However the difference in body weight of the two groups was relatively narrow (mean +/- SE; 26.93 +/- 0.16 vs. 23.11 +/- 0.27). In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).
Smoking is a significant factor affecting the pharmacokinetics of clopidogrel, following administration of a single 75 mg dose in healthy young volunteers. The study supports smoking-cessation recommendations. Further studies are required to evaluate the influence of smoking and body weight on the pharmacokinetics of the active metabolite of clopidogrel and on the clinical effects of any differences observed.

0 Bookmarks
 · 
94 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 5-40 % of patients treated with clopidogrel do not display an adequate antiplatelet response. Clopidogrel resistance may be caused by insufficient drug absorption or impaired metabolic activation of the drug. The aim of this study was to evaluate the pharmacokinetics of clopidogrel and its metabolites in plasma samples from patients treated with high and low doses of clopidogrel, to obtain a possible explanation for antiplatelet resistance. The study included patients receiving either a single 300 mg loading dose of clopidogrel (n = 17) or a 75 mg dose (n = 45) for at least 7 days before sample collection. The concentrations of clopidogrel and its metabolites-the inactive H3 and the pharmacologically active H4 isomers of the thiol metabolite and the inactive carboxylic acid metabolite-in plasma samples (stabilized with 2-bromo-3'-methoxyacetophenone) from three patients after 300 mg and from 41 patients after 75 mg of the drug were determined using a validated high-performance liquid chromatography method with tandem mass spectrometry. The non-stabilized samples from the remaining patients were analysed using a validated capillary electrophoresis method. The calculated concentrations were used to determine the pharmacokinetic parameters of the analytes. The pharmacodynamic response to clopidogrel treatment, expressed as adenosine diphosphate-induced platelet aggregation, was measured using a Multiplate analyser. The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data. Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min. A significant correlation was found between the C max of the active H4 isomer and platelet aggregation (p = 0.025). The C max of the active H4 isomer and platelet aggregation measured by the Multiplate analyser may serve as markers of the patient response to clopidogrel therapy.
    Clinical Pharmacokinetics 10/2013; · 5.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Exercise-induced anaphylaxis was first described as a particular form of physical allergy about 30 years ago. As its name indicates, this disease is characterized by anaphylaxis that has exercise as the only identified triggering factor. The symptoms can develop in the course of everyday actions, which are of course difficult to avoid, and very little effort may induce a reaction. The diagnosis can thus have a great impact on the patient's daily life, particularly since no efficient prophylactic treatment has been identified yet. In this article, we review current knowledge about exercise-induced anaphylaxis (clinical manifestations, possible and known pathophysiological mechanisms, treatment) and its main differential diagnosis: food-dependent exercise-induced anaphylaxis and cholinergic urticaria.
    Revue Francaise D Allergologie - REV FR ALLERGOL. 01/2011; 51(4):414-418.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the presented study was to look for a relationship between physicochemical parameters of selected drugs and the value of between-subject variability of area under the curve (AUCBSV). The analysis was performed for a group of 100 drugs prescribed in different disease entities in humans. At first, a direct correlation between 52 physicochemical parameters and AUCBSV was determined. In the next step, physicochemical parameters of the drugs calculated in silico were divided into quintile groups and a search for the correlation between the AUCBSV values for individual parameters in each quintile group and the number of the quintile was conducted. Only in case of 5 of the 52 parameters analyzed (partition coefficient octanol/water - XLogP, ionization potential - IP, globularity - Glob, polarizability - α, and polar surface area - PSA), it was possible to create an arithmetic expression $ [(X\log P + {\text{IP}} + {\text{Glob}})^{{{\text{Log}}\alpha}} - {\text{PSA}}] $ , for which the correlation with AUCBSV value was statistically significant (P < 0.05). Results of this study indicate that XLogP, α, IP, Glob, and PSA are a group of physicochemical parameters related to AUCBSV.
    Medicinal Chemistry Research 22(4). · 1.61 Impact Factor